JP2004529850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529850A5 JP2004529850A5 JP2002526365A JP2002526365A JP2004529850A5 JP 2004529850 A5 JP2004529850 A5 JP 2004529850A5 JP 2002526365 A JP2002526365 A JP 2002526365A JP 2002526365 A JP2002526365 A JP 2002526365A JP 2004529850 A5 JP2004529850 A5 JP 2004529850A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sexual dysfunction
- clathrate
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 41
- 201000001880 Sexual dysfunction Diseases 0.000 description 23
- 231100000872 sexual dysfunction Toxicity 0.000 description 23
- 150000003839 salts Chemical class 0.000 description 17
- 239000012453 solvate Substances 0.000 description 17
- 230000002265 prevention Effects 0.000 description 13
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical class C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 12
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 6
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 6
- 229960004425 sibutramine Drugs 0.000 description 6
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 4
- WQSACWZKKZPCHN-AWEZNQCLSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N)CC(C)C)CCC1 WQSACWZKKZPCHN-AWEZNQCLSA-N 0.000 description 3
- 230000037007 arousal Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000001107 psychogenic effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 description 1
- 229950003039 renzapride Drugs 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- -1 zakoprid Chemical compound 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/662,135 US6339106B1 (en) | 1999-08-11 | 2000-09-14 | Methods and compositions for the treatment and prevention of sexual dysfunction |
| PCT/US2001/028598 WO2002022114A2 (en) | 2000-09-14 | 2001-09-13 | Methods and compositions for the treatment and prevention of sexual dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529850A JP2004529850A (ja) | 2004-09-30 |
| JP2004529850A5 true JP2004529850A5 (enExample) | 2008-11-06 |
Family
ID=24656503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002526365A Pending JP2004529850A (ja) | 2000-09-14 | 2001-09-13 | 性機能不全の処置および防止のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6339106B1 (enExample) |
| EP (1) | EP1320360A1 (enExample) |
| JP (1) | JP2004529850A (enExample) |
| AU (2) | AU2001289062B2 (enExample) |
| CA (1) | CA2422246A1 (enExample) |
| WO (1) | WO2002022114A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| WO2006067060A2 (en) * | 2004-12-22 | 2006-06-29 | Ciba Specialty Chemicals Holding Inc. | Enantioselective synthesis of a sterically hindered amine |
| SG174079A1 (en) * | 2007-02-12 | 2011-09-29 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction |
| KR20130122023A (ko) * | 2007-02-12 | 2013-11-06 | 디엠아이 바이오사이언시스 인코포레이티드 | 트라마돌의 부작용을 감소시키는 방법 |
| JP2010527928A (ja) * | 2007-05-18 | 2010-08-19 | ヴィヴァス・インコーポレイテッド | ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3008993A1 (de) | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
| IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| JPS5940638A (ja) | 1982-08-30 | 1984-03-06 | Fuji Photo Film Co Ltd | 直接ポジ用ハロゲン化銀写真乳剤 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| GB8909209D0 (en) | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| DE69318196T2 (de) | 1992-01-28 | 1998-08-27 | Fujitsu Ltd | Plasma Farbanzeige-Vorrichtung von Oberflächenentladungs-Typ |
| US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
| EP0647134A4 (en) | 1992-06-23 | 1997-07-30 | Sepracor Inc | METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-). |
| EP0708639A4 (en) | 1992-06-23 | 1997-08-20 | Sepracor Inc | METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
| GB9402641D0 (en) | 1994-02-11 | 1994-04-06 | Boots Co Plc | Therapeutic agents |
| CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| AU3354895A (en) | 1994-09-19 | 1996-04-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel medicinal use of 5ht3 antagonist |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9524681D0 (en) | 1995-12-02 | 1996-01-31 | Knoll Ag | Chemical process |
| DE19632423A1 (de) | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
| GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| GB9619962D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| GB9619961D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| US5795880A (en) | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6323242B1 (en) * | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| AU3894600A (en) * | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
-
2000
- 2000-09-14 US US09/662,135 patent/US6339106B1/en not_active Expired - Fee Related
-
2001
- 2001-09-13 WO PCT/US2001/028598 patent/WO2002022114A2/en not_active Ceased
- 2001-09-13 AU AU2001289062A patent/AU2001289062B2/en not_active Ceased
- 2001-09-13 JP JP2002526365A patent/JP2004529850A/ja active Pending
- 2001-09-13 EP EP01968848A patent/EP1320360A1/en not_active Withdrawn
- 2001-09-13 CA CA002422246A patent/CA2422246A1/en not_active Abandoned
- 2001-09-13 AU AU8906201A patent/AU8906201A/xx active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5550101B2 (ja) | トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法 | |
| JP2007533686A5 (enExample) | ||
| JP5528705B2 (ja) | ヒトにおける早漏を治療するための方法 | |
| JP2010522135A (ja) | 医薬組成物 | |
| EP0996447B1 (en) | Combination therapy for modulating the human sexual response | |
| CA2440920C (en) | Use of tramadol to delay ejaculation | |
| CA2416480A1 (en) | Method for the treatment of climacteric disorders in women during or after the menopause | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2004529850A5 (enExample) | ||
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| US20080003275A1 (en) | Treatment of Premature Ejaculation | |
| US20140011838A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| US20140011837A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| US20100311785A1 (en) | Combination Therapy For Modulating The Human Sexual Response | |
| JP2000219626A (ja) | ケロイドおよび／または肥厚性瘢痕の治療剤 | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| AU2005100183A4 (en) | Treatment of premature ejaculation | |
| HK1028197B (en) | Combination therapy for modulating the human sexual response | |
| JP2010518052A (ja) | 性機能障害の予防および治療に有用な薬物の調製のための、ニューロキニンａのｎｋ２受容体に対する化合物である拮抗薬の使用 | |
| MXPA99010400A (en) | Combination therapy for modulating the human sexual response | |
| EA200800361A1 (ru) | Лечебно-профилактическое средство, обладающее антибактериальным и спермицидным действием | |
| HK1068549B (en) | Use of a tramadol material in the preparation of a medicament for delaying ejaculation |